Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Fluvastatin mitigates SARS-CoV-2 infection in human lung cells

Francisco J. Zapatero-Belinchón, Rebecca Moeller, Lisa Lasswitz, Marco van Ham, Miriam Becker, Graham Brogden, Ebba Rosendal, Wenjie Bi, Belén Carriquí, Koushikul Islam, Annasara Lenman, Antonia P. Gunesch, Jared Kirui, Thomas Pietschmann, Anna K Överby, Lothar Jänsch, View ORCID ProfileGisa Gerold
doi: https://doi.org/10.1101/2020.07.13.20152272
Francisco J. Zapatero-Belinchón
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
2Department of Clinical Microbiology, Virology, Umeå University, SE-90185 Umeå, Sweden
3Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, SE-90185 Umeå, Sweden
4Department of Biochemistry & Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Moeller
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
4Department of Biochemistry & Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Lasswitz
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
4Department of Biochemistry & Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco van Ham
5Cellular Proteome Research Group, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Becker
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
2Department of Clinical Microbiology, Virology, Umeå University, SE-90185 Umeå, Sweden
3Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, SE-90185 Umeå, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Brogden
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ebba Rosendal
2Department of Clinical Microbiology, Virology, Umeå University, SE-90185 Umeå, Sweden
6The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenjie Bi
5Cellular Proteome Research Group, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Belén Carriquí
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
4Department of Biochemistry & Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koushikul Islam
2Department of Clinical Microbiology, Virology, Umeå University, SE-90185 Umeå, Sweden
3Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, SE-90185 Umeå, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annasara Lenman
2Department of Clinical Microbiology, Virology, Umeå University, SE-90185 Umeå, Sweden
3Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, SE-90185 Umeå, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonia P. Gunesch
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
7Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
8German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jared Kirui
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
4Department of Biochemistry & Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Pietschmann
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
8German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna K Överby
2Department of Clinical Microbiology, Virology, Umeå University, SE-90185 Umeå, Sweden
6The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lothar Jänsch
5Cellular Proteome Research Group, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisa Gerold
1Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany
2Department of Clinical Microbiology, Virology, Umeå University, SE-90185 Umeå, Sweden
3Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, SE-90185 Umeå, Sweden
4Department of Biochemistry & Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gisa Gerold
  • For correspondence: gisa.gerold@tiho-hannover.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Clinical data of patients suffering from COVID-19 have indicated that statin therapy, used to treat hypercholesterolemia, is associated with a better clinical outcome. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that fluvastatin inhibited coronavirus infection, while other tested statins did not. Fluvastatin inhibited high and low pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Proteomic analyses of infected versus uninfected lung epithelial cells treated with fluvastatin, simvastatin, or rosuvastatin revealed that all tested statins modulated the cholesterol synthesis pathways without compromising the innate antiviral immune response. Strikingly, fluvastatin treatment uniquely affected the proteome of SARS-CoV-2 infected cells, specifically downregulating proteins that modulate protein translation and viral replication. These results suggest that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin may have a moderate beneficial effect on SARS-CoV-2 infection by modulating protein translation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

G.G. was supported by the Knut and Alice Wallenberg Foundation, the Federal Ministry of Education and Research together with the Ministry of Science and Culture of Lower Saxony through the Professorinnen Programm III, and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Projektnummer 158989968 - SFB 900 project C7 and the DFG project GE 2145/3-2 to G.G, the German Academic Exchange Service (DAAD) to J.K. and the Federal Ministry of Education and Research (project COVID-Protect, Projektnummer 01KI20143C) to F.J.Z.B. The work was further funded by the Infection Biology International PhD Program of Hannover Biomedical Research School to R.M., the German Centre for Infection Research (DZIF) to A.P.G. and T.P., the Helmholtz Alberta Initiative for Infectious Disease Research (HAI-IDR), the Shandong University Helmholtz International Laboratory to T.P, and the SciLifeLab/KAW national COVID-19 research program project grant 2020 and the Heart- and Lung foundation project grant for COVID-19 (project number 20200385) to A.K.O. and by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Unions Horizon 2020 research and innovation program under grant agreement No 871029.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We have obtained ethical permission from the regionala etikprovningsnamnden in Umea to isolate human bronchial epithelial cells (HBEC) from lung resection surgery (Dnr. 2014/395-31).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Whole cell proteomics data included

Data Availability

No additional data reported or deposited

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 04, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
Francisco J. Zapatero-Belinchón, Rebecca Moeller, Lisa Lasswitz, Marco van Ham, Miriam Becker, Graham Brogden, Ebba Rosendal, Wenjie Bi, Belén Carriquí, Koushikul Islam, Annasara Lenman, Antonia P. Gunesch, Jared Kirui, Thomas Pietschmann, Anna K Överby, Lothar Jänsch, Gisa Gerold
medRxiv 2020.07.13.20152272; doi: https://doi.org/10.1101/2020.07.13.20152272
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
Francisco J. Zapatero-Belinchón, Rebecca Moeller, Lisa Lasswitz, Marco van Ham, Miriam Becker, Graham Brogden, Ebba Rosendal, Wenjie Bi, Belén Carriquí, Koushikul Islam, Annasara Lenman, Antonia P. Gunesch, Jared Kirui, Thomas Pietschmann, Anna K Överby, Lothar Jänsch, Gisa Gerold
medRxiv 2020.07.13.20152272; doi: https://doi.org/10.1101/2020.07.13.20152272

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (44)
  • Cardiovascular Medicine (409)
  • Dentistry and Oral Medicine (68)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4817)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (188)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5284)
  • Intensive Care and Critical Care Medicine (327)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (112)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (203)
  • Oncology (439)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (128)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (771)
  • Public and Global Health (1800)
  • Radiology and Imaging (322)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)